Enzalutamide

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 3636 publications

Retraction Note: Comment on: "Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study".

Retraction Note: Comment on: "Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study".

Journal: World journal of urology

Published: January 21, 2026

Comparison of deep prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide.

Comparison of deep prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide.

Journal: Journal of comparative effectiveness research

Published: January 16, 2026

Glycolysis reprogramming predicts poor prognosis and drives therapy resistance via CLN6 in lethal prostate cancer.

Glycolysis reprogramming predicts poor prognosis and drives therapy resistance via CLN6 in lethal prostate cancer.

Journal: Acta biochimica et biophysica Sinica

Published: January 13, 2026

Patient-derived organoids based on targeted biopsy of primary prostate cancer: development, identification, and drug screening.

Patient-derived organoids based on targeted biopsy of primary prostate cancer: development, identification, and drug screening.

Journal: Annals of medicine

Published: December 17, 2025

Graded Notch Signaling Functions as a Rheostat of Lineage Plasticity and Therapy Resistance in Prostate Cancer.

Graded Notch Signaling Functions as a Rheostat of Lineage Plasticity and Therapy Resistance in Prostate Cancer.

Journal: bioRxiv : the preprint server for biology

Published: December 15, 2025

Therapy-induced PSMA2 Sensitizes Prostate Cancer Cells to Residual Androgen and Promotes Neuroendocrine Lineage Transformation.

Therapy-induced PSMA2 Sensitizes Prostate Cancer Cells to Residual Androgen and Promotes Neuroendocrine Lineage Transformation.

Journal: bioRxiv : the preprint server for biology

Published: December 15, 2025

Long-term trends in androgen-directed therapy in advanced prostate cancer: a 29-year national analysis.

Long-term trends in androgen-directed therapy in advanced prostate cancer: a 29-year national analysis.

Journal: International urology and nephrology

Published: December 12, 2025

Association Between Time to PSA Nadir, Radiologic Progression, and PSA Progression in mHSPC Patients Treated with Abiraterone or Enzalutamide.

Association Between Time to PSA Nadir, Radiologic Progression, and PSA Progression in mHSPC Patients Treated with Abiraterone or Enzalutamide.

Journal: Journal of clinical medicine

Published: December 11, 2025

Preclinical Efficacy of TSL2109 in Prostate Cancer Treatment and Overcoming Enzalutamide Resistance.

Preclinical Efficacy of TSL2109 in Prostate Cancer Treatment and Overcoming Enzalutamide Resistance.

Journal: Journal of medicinal chemistry

Published: December 09, 2025

Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK Trial.

Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK Trial.

Journal: The Journal of urology

Published: December 09, 2025

Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary Endpoints.

Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary Endpoints.

Journal: The Journal of urology

Published: December 05, 2025

A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases.

A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases.

Journal: Future oncology (London, England)

Published: November 28, 2025

Showing 1-12 of 3,636

Last Updated: 02/24/2026